SCHEMBL22607017

SCHEMBL22607017

Nc1c(-c2cccc3ccccc23)c2ccccc2c2c1oc1ccccc12

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.39
ALDH1A1 P00352 5/20 0.39
HPGD P15428 4/20 0.39
HSD17B10 Q99714 4/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 3/20 0.38
GAA P10253 3/20 0.38
ALOX15 P16050 1/20 0.37
ALOX5 P09917 2/20 0.35
LIMK1 P53667 1/20 0.35
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
KEAP1 Q14145 1/20 0.34
ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18266973 0.79 L3MBTL1 (0.42) ALDH1A1HPGDHSD17B10MAPTMEN1
SCHEMBL17944647 0.78 L3MBTL1 (0.46) DHFRALDH1A1HPGDHSD17B10MAPT
SCHEMBL12425609 0.78 ALOX5 (0.37) ALDH1A1HPGDHSD17B10MAPTMEN1
SCHEMBL29990703 0.78 TDP1 (0.45) DHFRALDH1A1HPGDHSD17B10MAPT
SCHEMBL18382876 0.78 TDP1 (0.45) DHFRALDH1A1HPGDHSD17B10MAPT
SCHEMBL22707092 0.78 ALOX5 (0.42) DHFRALDH1A1HPGDHSD17B10MAPT
SCHEMBL17932265 0.78 TDP1 (0.40) DHFRALDH1A1HPGDHSD17B10MAPT
SCHEMBL17943998 0.77 L3MBTL1 (0.41) DHFRALDH1A1HPGDHSD17B10MAPT
SCHEMBL19109824 0.77 ALOX5 (0.42) ALDH1A1HPGDHSD17B10MAPTMEN1
SCHEMBL24614656 0.77 GPR84 (0.39) ALDH1A1HPGDHSD17B10MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11706982-B2 Fused polycyclic compound, and preparation method and use thereof NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) 2023-07-18 US disclosed
US-11706982-B2 Fused polycyclic compound, and preparation method and use thereof NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) 2023-07-18 US disclosed
US-20200343455-A1 Fused Polycyclic Compound, and Preparation Method and Use Thereof NINGBO LUMILAN ADVANCED MATERIALS, CO., LTD. (CN) 2020-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11706982-B2 Fused polycyclic compound, and preparation method and use thereof INF2, INTS9, PYM1 DHFR 349/4885ALDH1A1 3407/4885HPGD 3219/4885
US-20200343455-A1 Fused Polycyclic Compound, and Preparation Method and Use Thereof INF2, INTS9, PYM1 DHFR 349/4885ALDH1A1 3407/4885HPGD 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.